Additional research on biomarkers in "Phase II study of panitumumab rechallenge in the third-line therapy in patients with KRAS wild-type metastatic colorectal cancer (JACCRO CC-09) "

Additional research on biomarkers in "Phase II study of panitumumab rechallenge in the third-line therapy in patients with KRAS wild-type metastatic colorectal cancer (JACCRO CC-09) " - JACCRO CC-09AR

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015916

Enrollment

Registered

2014-12-12

Start date

2014-12-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Interventions

Collecting blood 16mL at the time of before JACCRO CC-09 protocol treatment, 8 weeks after protocol treatment, and PD.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who are registered in JACCRO CC-09 study (UMIN000011440) (1) Approved to supply the section for this research by IRB. (2) Getting the informed consent from the patient.

Exclusion criteria

Exclusion criteria: (1) Patients who are regarded as inadequate for study enrollment by investigators (2) Patients who refuse to supply the section

Design outcomes

Primary

Measure	Time frame
Tumor-related gene variation analysis using plasma free DNA	—

Secondary

Measure	Time frame
The measurement in Cancer Panel	—

Countries

Japan

Contacts

Public ContactMasashi Fujii

Japan Clinical Cancer Reseach Organization (JACCRO) Research Office

cc09ar.dc@jaccro.or.jp03-6811-0433

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026

Additional research on biomarkers in &quot;Phase II study of panitumumab rechallenge in the third-line therapy in patients with KRAS wild-type metastatic colorectal cancer (JACCRO CC-09) &quot;